WEX Pharmaceuticals Inc.
TSX : WXI

WEX Pharmaceuticals Inc.

August 25, 2010 18:38 ET

WEX Announces Poster Presentation at Scientific Conference

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Aug. 25, 2010) - WEX Pharmaceuticals Inc. ("WEX" or the "Company") (TSX:WXI) announced today that WEX Research and Development staff and some participating clinical investigators will present a poster entitled "Long-Term Open-Label Study of Tetrodotoxin in Cancer Pain" at the 13th World Congress on Pain which will be held next week in Montreal, Canada. The World Congress on Pain is presented by the International Association for the Study of Pain and is the world's premier Congress devoted to research and treatment of pain. The poster will be presented at 2:45pm on August 31.

The poster and an accompanying abstract report interim results from WEX's TEC-006OL trial of Tetrodotoxin (TTX), which is a multicentre, open-label, continuation trial of the efficacy and safety of TTX in patients with inadequately controlled moderate to severe pain associated with cancer. Among the conclusions presented in the poster are that TTX is associated with major clinical benefit (analgesic effect) in patients with cancer pain, with no evidence of analgesic tolerance over time, and no evidence of cumulative toxicity. All patients enrolled in the TEC-006OL trial first participated in the ongoing TEC-006 trial, which is a multicentre, randomized, double-blind and placebo-controlled trial comparing the efficacy and safety of TTX to placebo in approximately 120 patients with moderate to severe inadequately controlled cancer-related pain.

About TTX

Tetrodotoxin (TTX) is a highly selective sodium channel blocker derived from the puffer fish. Sodium channels are found on nerves and are involved in the transmission of nerve impulses. Tetrodotoxin targets a subset of sodium channels found on nerves which conduct pain impulses. There are changes to this subset of sodium channels in chronic pain conditions. Tetrodotoxin is extremely potent, and much lower dosages are needed to produce an analgesic effect than with other drugs.

About WEX Pharmaceuticals Inc.

WEX Pharmaceuticals Inc. is dedicated to the discovery, development, manufacture and commercialization of innovative drug products to treat pain. The Company's principal business strategy is to derive drugs from naturally occurring toxins and develop proprietary products for the global market.

Forward Looking Statements and Information

Certain statements herein may contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Forward-looking statements or information appear in a number of places and can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate" or "believes" or variations of such words and phrases or statements that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are subject to such risks, uncertainties and other factors which may cause our actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. See our annual information form and our quarterly and annual management's discussion and analysis for additional information on risks and uncertainties relating to the forward-looking statements and information. There can be no assurance that forward-looking statements or information referenced herein will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements or information. Also, many of the factors are beyond the control of the Company. Accordingly, readers should not place undue reliance on forward-looking statements or information. All forward-looking statements and information made herein, are qualified by this cautionary statement.

Contact Information

  • WEX Pharmaceuticals Inc.
    Larry Gontovnick, Ph.D.
    Vice President, Research & Development
    (250) 857-4570
    www.wexpharma.com